Evidence map›Paper›PMID 33603203›Full record

ArticleNature biotechnology2022

Robust decomposition of cell type mixtures in spatial transcriptomics.

Dylan M Cable, Evan Murray, Luli S Zou, Aleksandrina Goeva, Evan Z Macosko, Fei Chen, Rafael A Irizarry

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Nature biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06625203 (Multi Omics and Spatial Atlas In Cancer), which is not on this map. Cited by 949 papers.

0numbers the graph read from it
0cells of the map it votes in
949citing papers in PubMed
67.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06625203 recruitingnot on this mapstarted 2023, after this paper: background citation

Multi Omics and Spatial Atlas In Cancer

TypeobservationalSponsorOWKINRan2023 to 2028Enrolled7,000ConditionsDiffuse Large B Cell Lymphoma, Solid Tumor Cancer
3 · Its place in the literature

Who cites it

949 citing papers in PubMed, 1,307 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cell plasticity in cancer and therapy resistance.Experimental & molecular medicine · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

889 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Dylan M CableDepartment of Electrical Engineering and Computer Science, MIT, Cambridge, MA, USA.
Evan MurrayBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Luli S ZouBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Aleksandrina GoevaBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Evan Z MacoskoBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2794-5165
Fei Chen *Broad Institute of Harvard and MIT, Cambridge, MA, USA. chenf@broadinstitute.org.ORCID http://orcid.org/0000-0003-2308-3649
Rafael A Irizarry *Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA. rafa@ds.dfci.harvard.edu.ORCID http://orcid.org/0000-0002-3944-4309
Broad Institute · USDana-Farber Cancer Institute · US

Funding

Supplement: Enhancing Community Contributions to Bioconductor With Build System Containerization and a GPU for TestingU24HG004059 · NHGRI · DANA-FARBER CANCER INST · PI VINCENT JAMES CAREY, Rafael Angel Irizarry · 2021 to 2026
$7.3M
COVID19 Slide-seqR01HG010647 · NHGRI · BROAD INSTITUTE, INC. · PI Fei Chen, Evan Z Macosko · 2019 to 2026
$6.0M
Data Analysis Tools for Emerging High-Throughput TechnologiesR35GM131802 · NIGMS · DANA-FARBER CANCER INST · PI Rafael Angel Irizarry · 2019 to 2026
$4.1M
Overcoming bias and unwanted variability in next generation sequencingR01HG005220 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI IRIZARRY, RAFAEL ANGEL · 2010 to 2018
$3.6M
Next Generation Computational Tools for Functional GenomicsR01HG011139 · NHGRI · DANA-FARBER CANCER INST · PI IRIZARRY, RAFAEL ANGEL · 2020 to 2024
$3.5M
Characterizing glioma heterogeneity with novel multiplexed nanoscale imaging technologiesDP5OD024583 · OD · BROAD INSTITUTE, INC. · PI CHEN, FEI · 2017 to 2021
$2.2M
IMAT-ITCR Collaboration: An integrated experimental and computational platform for analyzing the spatial organization of tumor clonesR33CA246455 · NCI · BROAD INSTITUTE, INC. · PI ASHENBERG, ORR, CHEN, FEI · 2020 to 2022
$1.4M
NCI NIH HHS R33 CA246455NHGRI NIH HHS R01 HG005220NHGRI NIH HHS R01 HG010647NHGRI NIH HHS R01 HG011139NHGRI NIH HHS U24 HG004059NIGMS NIH HHS R35 GM131802NIH HHS DP5 OD024583
6 · The paper itself

Abstract

A limitation of spatial transcriptomics technologies is that individual measurements may contain contributions from multiple cells, hindering the discovery of cell-type-specific spatial patterns of localization and expression. Here, we develop robust cell type decomposition (RCTD), a computational method that leverages cell type profiles learned from single-cell RNA-seq to decompose cell type mixtures while correcting for differences across sequencing technologies. We demonstrate the ability of RCTD to detect mixtures and identify cell types on simulated datasets. Furthermore, RCTD accurately reproduces known cell type and subtype localization patterns in Slide-seq and Visium datasets of the mouse brain. Finally, we show how RCTD's recovery of cell type localization enables the discovery of genes within a cell type whose expression depends on spatial environment. Spatial mapping of cell types with RCTD enables the spatial components of cellular identity to be defined, uncovering new principles of cellular organization in biological tissue. RCTD is publicly available as an open-source R package at https://github.com/dmcable/RCTD .

Indexed as

Single-Cell AnalysisTranscriptomeAnimalsExome SequencingMiceSequence Analysis, RNASoftware

Identifiers

PMID33603203
PMCPMC8606190
OpenAlexW3129476455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.